Navigation Links
Researchers find chink in the armor of viral 'tummy bug'

Researchers at Griffith University's Institute for Glycomics in collaboration with colleagues at the University of Melbourne have moved a step closer to identifying a broad spectrum treatment for the dreaded 'viral tummy bug' or rotavirus.

These highly-infectious viruses are the leading cause of severe diarrhoea in young children, responsible for thousands of hospitalisations in the developed world, and hundreds of thousands of deaths each year in developing countries.

Institute Executive Director Professor Mark von Itzstein said research findings published in the world-leading Chemical Biology journal Nature Chemical Biology this week demanded a total rethink of how these viruses work.

"Rotaviruses are thought to infect the bodies by sticking to certain types of sugars called sialic acids on the surface of our stomach cells. They then enter cells and reproduce rapidly, causing illness," he said.

"Rotavirus vaccines are still in their infancy, as problems emerged with the first vaccine that was trialled a number of years ago. While other vaccines are now in clinical use, new directions are required in the development of potential drugs to prevent or treat this deadly virus."

He said that to better understand how carbohydrates are involved in rotavirus infection, researchers had focussed on treating mammalian cells with a protein called sialidase which cuts these surface sugars so the virus cannot attach.

Previous to his group's work most scientists believed only some of the many strains of rotavirus infection could be prevented with sialidase treatment while others were apparently immune to its effects.

This led to the conclusion that some viruses depend on sialic acid to infect the body while others were thought to cause infection independent of sialic acid.

"Unsuccessful attempts to reduce rotavirus infection with this treatment led scientists to group rotaviruses into two classes: 'sialidase-sensitive' and 'sialidase-insensitive' strains," he said.

The team used nuclear magnetic resonance spectroscopy, 3D modelling and cell-based assays to observe the interaction between the virus and host cells.

"We found that a human strain previously through insensitive to sialidase does in fact recognise and bind to sialic acid, but it is a sialic acid not accessible to sialidase treatment." Professor von Itzstein said.

"This reveals that there is a common chink in the armour of these rotaviruses.

"This discovery is the first step in designing a broad-spectrum drug able to exploit this weakness to combat many types of human and animal rotaviruses."


Contact: Jeannette Langan
Research Australia

Related biology news :

1. Biomedical researchers create artificial human bone marrow in a test tube
2. Princeton researchers discover new type of laser
3. UT Southwestern researchers identify gene linked to inherited form of fatal lung disease
4. James Thomson receives 2008 Massry Prize honoring stem cell researchers
5. Researchers push nature beyond its limits to create higher-density biofuels
6. Researchers advance knowledge of little nano-machines in our body
7. No quick or easy technological fix for climate change, researchers say
8. Researchers find natures shut-off switch for cellulose production
9. Researchers compile molecular manual for 100s of inherited diseases
10. Pitt researchers create non-toxic clean-up method for potentially toxic nano materials
11. Researchers identify new anti-tumor gene
Post Your Comments:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... that focuses on a daily routine for managing the ... their medication can affect the way the body absorbs ... to their a daily routine are important. The goal ... help patients better manage their hypothyroidism by establishing a ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant ... of the Chief Scientist (OCS). This grant, the second this ... 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
Breaking Biology Technology: